HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use TOVIAZ safely and effectively. See full prescribing information for TOVIAZ.
TOVIAZ® (fesoterodine fumarate) extended-release tablets, for oral use
Initial U.S. Approval: 2008
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Extended-release tablets: 4 mg and 8 mg (3)
WARNINGS AND PRECAUTIONS
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.